Accepted Manuscript

Editorial Commentary – The ODYSSEY Outcomes Trial: Clinical Implications and Exploration of the Limits of What Can be Achieved Through Lipid Lowering

Kevin C. Maki, PhD, CLS, FNLA

PII: \$1933-2874(18)30245-9

DOI: 10.1016/j.jacl.2018.05.016

Reference: JACL 1323

To appear in: Journal of Clinical Lipidology

Received Date: 12 April 2018 Revised Date: 17 May 2018 Accepted Date: 21 May 2018

Please cite this article as: Maki KC, Editorial Commentary – The ODYSSEY Outcomes Trial: Clinical Implications and Exploration of the Limits of What Can be Achieved Through Lipid Lowering, *Journal of Clinical Lipidology* (2018), doi: 10.1016/j.jacl.2018.05.016.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



ACCEPTED MANUSCRIPT

Editorial Commentary – The ODYSSEY Outcomes Trial: Clinical Implications and Exploration of the Limits of What Can be Achieved Through Lipid Lowering

Kevin C Maki, PhD, CLS, FNLA¹

¹Midwest Biomedical Research/Center for Metabolic and Cardiovascular Health, Glen Ellyn, IL

Correspondence:

Kevin C Maki, PhD, CLS, FNLA

Midwest Biomedical Research: Center for Metabolic and Cardiovascular Health

489 Taft Ave., Suite 202

Glen Ellyn, IL 60137

Tel: 630-469-6600

E-mail: kmaki@mbclinicalresearch.com

Keywords: acute coronary syndromes, alirocumab, cardiovascular disease, low-density lipoprotein cholesterol, proprotein convertase subtilisin kexin type 9

Download English Version:

https://daneshyari.com/en/article/11008562

Download Persian Version:

https://daneshyari.com/article/11008562

<u>Daneshyari.com</u>